Research programme: melanocyte stimulating hormone analogues - Zengen
Alternative Names: CZEN-006; Melanocortin-1 receptor agonists research programme - Zengen; Melanocortin-3 receptor agonists research programme - Zengen; Melanocyte stimulating hormone analogues research programme - Zengen; Research programme: melanocortin-1 receptor agonists - Zengen; Research programme: melanocortin-3 receptor agonists - ZengenLatest Information Update: 16 Jul 2016
At a glance
- Originator Zengen
- Class Pituitary hormones
- Mechanism of Action Melanocortin receptor agonists; Melanocyte-stimulating hormone stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Brain oedema; CNS disorders; Inflammation; Mesothelioma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Brain-oedema in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in CNS-disorders in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in USA